Summarized by Masters of Longevity from Peter Attia Blog.
Peptides and pharma: a deep-dive article tracing patent and development histories to challenge common beliefs about industry neglect.
![The [almost] unbelievable relationship between “big pharma” and gray-market peptides](https://www.masters-of-longevity.com/static/source-images/6aa5523404659c3c4db2766e.webp)
Key Takeaways
- Many popular gray-market peptides have patent or development ties to the pharmaceutical industry, contradicting claims they are entirely ignored by pharma.
- Peptides can be and have been patented and pursued commercially, so lack of investment is not always the reason for limited clinical evidence.
- Evaluating peptide safety and efficacy requires examining documented development histories rather than assuming absence of pharma interest implies scientific promise.
